PreveCeutical's Subsidiary, BioGene Therapeutics, Appoints President
PreveCeutical Medical has announced the appointment of Dr. Mariya Georgieva as President of its wholly-owned subsidiary BioGene Therapeutics, effective November 11, 2024. Dr. Georgieva joins from AstraZeneca where she served as Director of Diagnostic Alliances in Precision Medicine R&D since 2019. Previously, she headed applications and business development at Oxford-based ONI. She holds a PhD in Biomedical Science from the University of Montpellier, specializing in single-molecule fluorescence tools for studying epigenetic alterations.
PreveCeutical Medical ha annunciato la nomina della Dr.ssa Mariya Georgieva come Presidente della sua controllata interamente posseduta BioGene Therapeutics, con effetto dall'11 novembre 2024. La Dr.ssa Georgieva proviene da AstraZeneca, dove ha ricoperto il ruolo di Direttore delle Alleanze Diagnostiche nell'R&D di Medicina di Precisione dal 2019. In precedenza, ha guidato le applicazioni e lo sviluppo commerciale presso ONI, con sede a Oxford. Possiede un dottorato in Scienza Biomolecolare conseguito presso l'Università di Montpellier, specializzandosi in strumenti di fluorescenza a singola molecola per lo studio delle alterazioni epigenetiche.
PreveCeutical Medical ha anunciado el nombramiento de la Dra. Mariya Georgieva como Presidenta de su subsidiaria de propiedad total BioGene Therapeutics, a partir del 11 de noviembre de 2024. La Dra. Georgieva proviene de AstraZeneca, donde se desempeñó como Directora de Alianzas Diagnósticas en I+D de Medicina de Precisión desde 2019. Anteriormente, lideró aplicaciones y desarrollo comercial en ONI, con sede en Oxford. Tiene un doctorado en Ciencias Biomédicas de la Universidad de Montpellier, especializándose en herramientas de fluorescencia de molécula única para el estudio de las alteraciones epigenéticas.
프레베큐티컬 메디컬은 2024년 11월 11일부터 그들의 전액 출자 자회사인 바이오진 테라퓨틱스의 사장으로 드. 마리야 게오르기바를 임명했다고 발표했습니다. 게오르기바 박사는 2019년부터 정밀 의학 연구 개발에서 진단 제휴 담당 이사로 근무했던 AstraZeneca에서 합류했습니다. 이전에는 옥스포드에 본사를 둔 ONI에서 응용 및 사업 개발을 책임졌습니다. 그녀는 몽펠리에 대학교에서 생물 의학 과학 박사 학위를 취득하였으며, 에피제네틱 변화 연구를 위한 단일 분자 형광 도구를 전문으로 하고 있습니다.
PreveCeutical Medical a annoncé la nomination de Dr. Mariya Georgieva au poste de Présidente de sa filiale entièrement détenue BioGene Therapeutics, à compter du 11 novembre 2024. Dr. Georgieva rejoint AstraZeneca, où elle a occupé le poste de Directrice des Alliances Diagnostiques au sein de la R&D en Médecine de Précision depuis 2019. Auparavant, elle a dirigé les applications et le développement commercial chez ONI, basé à Oxford. Elle détient un doctorat en Sciences Biomédicales de l'Université de Montpellier, spécialisée dans les outils de fluorescence à molécules uniques pour l'étude des altérations épigénétiques.
PreveCeutical Medical hat die Ernennung von Dr. Mariya Georgieva zur Präsidentin ihrer hundertprozentigen Tochtergesellschaft BioGene Therapeutics, die am 11. November 2024 in Kraft tritt, bekannt gegeben. Dr. Georgieva wechselt von AstraZeneca, wo sie seit 2019 als Direktorin für Diagnostik-Allianzen in der Forschung und Entwicklung der Präzisionsmedizin tätig war. Zuvor leitete sie Anwendungen und Geschäftsentwicklung bei dem in Oxford ansässigen Unternehmen ONI. Sie hat einen Doktortitel in Biowissenschaften von der Universität Montpellier und spezialisiert sich auf Einzelmolekül-Fluoreszenzwerkzeuge zur Untersuchung epigenetischer Veränderungen.
- Appointment of experienced executive from major pharmaceutical company AstraZeneca
- Strategic addition to advance siRNA therapy development in diabetes and obesity
- None.
Vancouver, British Columbia--(Newsfile Corp. - November 13, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly-owned subsidiary BioGene Therapeutics Inc. has appointed Dr. Mariya Georgieva as President effective on 11 November, 2024.
Stephen Van Deventer, Chairman and CEO of PreveCeutical commented "I am extremely pleased to have Dr. Georgieva become part of BioGene as we advance our siRNA therapy in diabetes and obesity. Her strengths and talent will be extremely valuable to the company moving forward."
Dr. Georgieva is joining BioGene from AstraZeneca Ltd. In the UK where she has been Director, Diagnostic Alliances within Precision Medicine R&D since 2019. Prior to AstraZeneca she was with the Oxford-based startup ONI (OXFORD NANOIMAGING LTD.), UK as head of applications and business development. Dr. Georgieva holds a PhD in Biomedical Science from the University of Montpellier (France), where she has developed single-molecule fluorescence tools to study the interplay between epigenetic alterations and the biophysical properties of chromatin during development.
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.
About BioGene Therapeutics Inc.
BioGene Therapeutics Inc. ("BioGene") is a Texas-based life sciences company focused on advancing innovative therapies in metabolic health and gene-based treatments. As a key component of BioGene's expansion, BioGene Australia operates as a wholly-owned subsidiary of BioGene in Texas, leveraging the strategic benefits of Australia's
On Behalf of the Board of Directors,
PreveCeutical Medical Inc. & BioGene Therapeutics Inc.
"Stephen Van Deventer"
Chairman & Chief Executive Officer
For further information, please contact:
Stephen Van Deventer
(604) 306-9669
info@PreveCeutical.com
Forward-Looking Statements:
This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding the advancement of our siRNA therapy; and PreveCeutical's aim to be a leader in preventive health sciences. The forward-looking statements reflect management's current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including adverse market conditions and other factors beyond the control of the parties. Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company, including regulations and policies affecting the biotechnology or pharmaceutical industry adversely affecting the future results or performance of PreveCeutical or BioGene. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/229657
FAQ
Who is the new President of BioGene Therapeutics, PreveCeutical's subsidiary (PRVCF)?
What was Dr. Georgieva's role at AstraZeneca before joining PreveCeutical (PRVCF)?
What therapeutic areas is BioGene Therapeutics (PRVCF) focusing on?
